Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
03:30pm, Friday, 26'th Jun 2020
Is (ALLO) Outperforming Other Medical Stocks This Year?
Allogene Therapeutics Investor Presentation - Slideshow
06:03pm, Thursday, 25'th Jun 2020
The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this event.
Bayer paying up to $10.9B to settle Monsanto weedkiller case
09:20am, Thursday, 25'th Jun 2020
German pharma giant Bayer says it’s paying up to $10.9 billion to settle litigation over subsidiary Monsanto’s weedkiller Roundup
US Co Will Pay Up To $10.9 Billion To Settle Litigation Against Its Weedkiller Over Claims of Causing Cancer
02:37am, Thursday, 25'th Jun 2020
The company said the settlement over Roundup, which is made by its Monsanto subsidiary, involves about 125,000 filed and unfiled claims. Under the agreement, Bayer will make a payment of $8.8 billion
Bayer paying up to $10.9 billion to settle Monsanto weedkiller case
02:35am, Thursday, 25'th Jun 2020
German pharma giant Bayer says it’s paying up to resolve litigation over claims that the weedkiller Roundup causes cancer.
Bayer paying up to $10.9B to settle Monsanto weedkiller case
09:07pm, Wednesday, 24'th Jun 2020
BERLIN (AP) — Bayer said Wednesday that it will pay up to $10.9 billion to settle litigation over the weedkiller Roundup, which has faced thousands of lawsuits over claims it causes cancer. Bayer sa
Bayer Agrees to Settle Roundup Lawsuits, Will Pay Over $10 Billion
06:22pm, Wednesday, 24'th Jun 2020
Bayer agreed to pay up to $10.9 billion to settle tens of thousands of lawsuits alleging Roundup, a ...
Bayer agrees to settle Roundup lawsuits
05:02pm, Wednesday, 24'th Jun 2020
In their lawsuits, users blame Roundup for their non-Hodgkin’s lymphoma and other cancers.
Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com
12:00am, Wednesday, 24'th Jun 2020
The
“Our goal is to remain at the forefront of innovation in allogeneic cell therapy, and these studies inform our ability to optimize AlloCAR T therapy for both hematologic and solid tumors,” said Ba
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
12:30pm, Monday, 22'nd Jun 2020
FLT3-Directed AlloCAR T™ Therapy Demonstrated Potent Anti-Leukemic Activity in Pre-Clinical Models Without Evidence of Off-Target Activity SOUTH SAN FRANCISCO, Calif., June.
Here's How Much Investing $1,000 In The 2018 Moderna IPO Would Be Worth Today
12:00am, Monday, 22'nd Jun 2020
Investors who owned stocks in the past year and a half generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return since Dec. 7, 2018 is 21.4%....
BNP Paribas Arbitrage SA Boosts Position in Allogene Therapeutics Inc (NASDAQ:ALLO)
05:40am, Saturday, 20'th Jun 2020
BNP Paribas Arbitrage SA boosted its holdings in Allogene Therapeutics Inc (NASDAQ:ALLO) by 289.1% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 21,686 s
Xconomy: Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies
11:46pm, Wednesday, 17'th Jun 2020
The cancer cell therapies available today are made by tweaking a patient’s own immune cells to better recognize and fight the disease. Orca Bio is
Orca Bio Emerges as $1 Billion-Plus Biotech With Mystery Backer - BNN Bloomberg
01:02pm, Wednesday, 17'th Jun 2020
Orca Bio raised $192 million from Lightspeed Venture Partners and an unnamed investor for its experimental cell therapy platform.
